Removal of APIs and bacteria from hospital wastewater by MBR plus O 3, O3 + H2O2, PAC or ClO2

Water Science and Technology

Volumn 67, Issue 4, 2013, Pages 854-862

  Nielsen, U ^a   Hastrup, C ^a   Klausen, M M ^a   Pedersen, B M ^a   Kristensen, G H ^a   Jansen, J L C ^b   Bak, S N ^c   Tuerk, J ^d  

^a DHI   (Denmark)

^b LUND UNIVERSITY   (Sweden)

^c Grundfos DK AS   (Denmark)

^d Institute of Energy and Environmental Technology IUTA   (Germany)

Author keywords

Advanced oxidation processes; Bacteria; Hospital wastewater; MBR; Pharmaceuticals

Indexed keywords

ACTIVE PHARMACEUTICAL INGREDIENTS; ADVANCED OXIDATION PROCESSES; ANTIBIOTIC-RESISTANT BACTERIA; HOSPITAL WASTEWATER; MBR; MEMBRANE BIO REACTOR (MBR); POWDERED ACTIVATED CARBON; PREDICTED NO-EFFECT CONCENTRATIONS;

ACTIVATED CARBON; ACTIVATED CARBON TREATMENT; ANTIBIOTICS; BACTERIA; DRUG PRODUCTS; ESCHERICHIA COLI; HOSPITALS; OZONE;

EFFLUENTS;

ACTIVATED CARBON; AMIDOTRIZOATEACID; CHEMICALS AND DRUGS; CHLORINE DIOXIDE; CIPROFLOXACIN; HYDROGEN PEROXIDE; IODINATED CONTRAST MEDIUM; IOHEXOL; IOPROMIDE; IOVERSOL; OZONE; SULFAMETHIZOLE; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG;

ACTIVATED CARBON; BIOREACTOR; COLIFORM BACTERIUM; COST-BENEFIT ANALYSIS; DRUG; HOSPITAL SECTOR; HYDROGEN PEROXIDE; MEMBRANE; OXIDATION; OZONE; POLLUTANT REMOVAL; WASTEWATER; WATER TREATMENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CONTAMINATION; ENTEROCOCCACEAE; ESCHERICHIA COLI; HOSPITAL WASTE; MARINE ENVIRONMENT; MEMBRANE REACTOR; WASTE WATER MANAGEMENT;

BIOREACTORS; CHARCOAL; CHLORINE COMPOUNDS; DISINFECTION; HYDROGEN PEROXIDE; MEDICAL WASTE; OXIDES; OZONE; PHARMACEUTICAL PREPARATIONS; WASTE WATER; WATER POLLUTANTS, CHEMICAL;

EID: 84874927702     PISSN: 02731223     EISSN: None     Source Type: Journal    
DOI: 10.2166/wst.2012.645     Document Type: Article

References (20)

1. Bartelt-Hunt, S. L., Snow, D. D., Damon, T., Shockley, J. & Hoagland, K. 2009 The occurrence of illicit and therapeutic pharmaceuticals in wastewater effluent and surface waters in Nebraska. Environmental Pollution 157 (3), 786 - 791.
2. Beier, S., Cramer, C., Mauer, C., Köster, S., Schröder, H.& Pinnekamp, J. 2012 MBR technology: A promising approach for the (pre-)treatment of hospital wastewater. Water Science and Technology 65 (9), 1648 - 1653.
3. Danish Nature Agency 2011 Action Plan for Hospital Waste Water. Danish Environmental Protection Agency. Available from: http://www.naturstyrelsen.dk/ NR/rdonlyres/9C3781 61- 2BD9-44C8-9 14E-9C1 7B0327278/0/O5hospitalsspildevand. pdf (accessed March 2, 2012).
4. DHI 2010 Ecotoxicological Evaluation Performed by DHI. DHI, Department of Environmental Risk Assessment, Horsholm, Denmark.
5. Escher, B. I., Baumgartner, R., Koller, M., Treyer, K., Lienert, J. & McArdell, C. 5. 2011 Environmental toxicology and risk assessment of pharmaceuticals from hospital wastewater. Water Research 45, 75 - 92.
6. EU 2012 Proposal for a Directive of The European Parliament and of the Council amending Directives 2000/60/EC and 2008/ 105/EC as regards priority substances in the field of water policy. European Commission 31.01.2012.
7. FASS 2011 Miljöinformation. Environmental information about pharmaceuticals provided by Swedish LIF. Available from: http://www.fass.se/LIF/ miljo/miljoinfo.jsp (accessed September to December 2011).
8. Fredskilde, J. W. L. & Nielsen, U. 2008 Measurement for selected pharmaceuticals in the effluent of Lynetten WWTP. Copenhagen Energy, the Lynetten Partnership, and the Municipality of Copenhagen Joint Report.
9. Jean, J., Perrodin, Y., Pivot, C., Trepo, D., Perreaud, M., Droguet, J., Tissot-Guerraz, F. & Locher, F. 2012 Identification and prioritization of bioaccumuable pharmaceutical substances discharged in hospital effluents. Journal of Environmental Management 103 (2012), 113 - 121.
10. MST 2007 Limiting Human Pharmaceutical Residues and Antibiotic Resistance in Wastewater with Focus on Reduction at the Source.
11. Danish EPA (in Danish). www2. mstdk/Udgiv/publikationer/2007/978-87-7052- 588-6/pdf/ 978-87-7052-589-3.pdf.
12. MST 2010 Order on Environmental Quality Standards for Water Areas and Requirements for Emissions of Pollutants to Wateiways, Lakes and the Sea. Order Number 1022 of 25/ 08/2010 (BEK nr 1022 af 25/08/2010).
13. Danish EPA. https:// www.retsinformation.dk/Forms/R07 10.aspx?id= 132956
14. MST 2011 Environmental Assessment of Specialized Pharmaceuticals in Hospital Wastewater. Danish EPA (in Danish). http://www. naturstyrelsen.dk/ NRlrdonlyres/FD2E46B9-2803-4DB3- A26A-98096C97BF4D/124881/ SpecialmedicinFlNALnyigen. pdf.
15. Ottoson, J., Hansen, A., Björlenius, B., Norder, H. & Stenström, T. A. 2006 Removal of viruses, parasitic protozoa and microbial indicators in conventional and membrane processes in a wastewater pilot plant Water Research 40, 1449 - 1457.
16. Radjenovic, J., Petrovic, M.& BarcelO, D. 2009 Fate and distribution of pharmaceuticals in wastewater and sewage sludge of conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment Water Research 43, 831 - 841.
17. Richardson, D. S. & Ternes, T. A. 2011 Water analysis: Emerging contaminants and current issues. Analytical Chemistry 83, 4614 - 4648.
18. Special Issue: Fundamental and Applied Reviews in Analytical Chemistry. SFT 2006 Initial assessment of eleven pharmaceuticals using the EMEA guideline in Norway. Norwegian Pollution Control Authority, Report TA-2216/2006.
19. SFT 2009 Environmental screening of selected organic compounds 2008. Human and hospital-use pharmaceuticals, aquaculture medicines and personal care products. Norwegian Pollution Control Authority, SPFO-rapport. 1046/2009, TA-2508/2009.
20. Wahlberg, C., Björlenius, B. & Paxéus, N. 2010 Pharmaceutical Residues in Stockholm Water Environment - Occurrence, mitigations and treatment of waste water. Stockholm Vatten (in Swedish).